Edimer Pharmaceuticals' Grant

Edimer Pharmaceuticals raised a round of funding on November 01, 2010. Investors include Qualifying Therapeutic Discovery Project.

Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). XLHED is a rare orphan disease that causes a range of symptoms including…

Articles about Edimer Pharmaceuticals' Grant: